KTX-582

KTX-582 is an investigational **oral small-molecule proteolysis-targeting chimera therapy** developed by **Kymera Therapeutics** for **MYD88-mutant diffuse large B-cell lymphoma** and related B-cell malignancies. It is designed to induce targeted degradation of **interleukin-1 receptor-associated kinase 4** and the IMiD substrate **Ikaros**, producing dual suppression of innate immune signaling and lymphoid transcriptional programs. Preclinically, KTX-582 has shown potent degradation activity, induction of apoptosis in MYD88-mutant DLBCL cell lines, and tumor regressions in lymphoma models, supporting its positioning as a targeted antineoplastic degrader program.